FDA Clears NMP22 BladderChek for Monitoring of Bladder Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 9
Volume 11
Issue 9

NEWTON, Mass-Matritech Inc. has received clearance from the US Food and Drug Administration to market NMP22 BladderChek for monitoring patients with a history of bladder cancer.

 NEWTON, Mass—Matritech Inc. has received clearance from the US Food and Drug Administration to market NMP22 BladderChek for monitoring patients with a history of bladder cancer.

The test brings rapid detection into the urologist’s office through the use of proteomics technology, the company said in a news release. Four drops of urine are placed on the BladderChek cassette to detect the presence of NMP22, a nuclear matrix protein correlated with bladder cancer.

Clinical trial results reviewed by the FDA showed that NMP22 Bladder-Chek detected 4 times more early-stage bladder tumors and 2.5 times more life-threatening, high-grade tumors than cytology. The test is used in conjunction with cystoscopy.

Related Videos
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content